Valeritas Holdings IPO

3/23/2017

IPO

$53,000,000

We currently anticipate that we will use approximately $38.0 million of the net proceeds received by us to support ongoing sales and marketing activities for V-Go and to expand our sales and marketing infrastructure. We anticipate we will use approximately $10.0 million of the net proceeds received by us to fund research, development and engineering activities and manufacturing capabilities, which we expect to include the further development of our V-Go Prefill and V-Go Link products, although we expect that we will need to seek additional capital to complete their development and commercialization. We expect that the remaining net proceeds will be used for working capital and other general corporate purposes.

Publicly-held

Medical Devices & Instruments

750 Route 202 South 600
Bridgewater, NJ 08807
USA

Valeritas (NASDAQ: VLRX) is a medical technologies company serving the fast-growing diabetes market. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals.